Compass Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Compass Therapeutics, Inc. on June 11, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Boston, Massachusetts.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The stockholders voted on two primary proposals:
- Proposal 1: Election of Directors. Three Class II nominees were elected to serve until the 2028 Annual Meeting.
- Carl L. Gordon, Ph.D., C.F.A. Received 80,657,849 votes For, 4,244,164 Withheld, and 29,432,541 Broker Non-votes.
- Philip J. Ferneau, M.B.A. J.D. Received 58,301,963 votes For, 26,600,050 Withheld, and 29,432,541 Broker Non-votes.
- James P. Boylan, M.B.A. Received 83,645,920 votes For, 1,256,093 Withheld, and 29,432,541 Broker Non-votes.
- Proposal 2: Ratification of Auditors. Stockholders ratified the appointment of CohnReznick, LLP as the independent registered public accounting firm for the year ending December 31, 2025.
- Votes For: 114,283,119
- Votes Against: 28,647
- Votes Abstained: 22,788
- Broker Non-votes: 0
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the outcome of the shareholder vote.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Review the definitive proxy statement (Form DEF 14A) filed on April 29, 2025, for detailed biographies of the elected directors and the rationale for the auditor appointment.
- Note the significant number of broker non-votes (29,432,541) on the director election, indicating shares held in street name where brokers lacked discretionary voting authority.
- Confirm the tenure of the newly elected directors, which extends through the 2028 Annual Meeting.